China Jo-Jo Drugstores, Inc. (CJJD)
USD 1.82
(0.91%)
USD 1.82
(0.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 1.22 Million USD | 106.15% |
| 2023 | -19.96 Million USD | -1589.35% |
| 2022 | -579.92 Thousand USD | 92.78% |
| 2021 | -6.07 Million USD | -74.0% |
| 2020 | -3.66 Million USD | -404.69% |
| 2019 | 266.56 Thousand USD | 107.84% |
| 2018 | -15.05 Million USD | -534.7% |
| 2017 | -4.24 Million USD | -376.5% |
| 2016 | 1.99 Million USD | -85.42% |
| 2015 | 4.52 Million USD | 156.62% |
| 2014 | -16.81 Million USD | -18.65% |
| 2013 | -9.81 Million USD | -166.82% |
| 2012 | 12.82 Million USD | 1.02% |
| 2011 | 12.79 Million USD | -6.21% |
| 2010 | 13.2 Million USD | 46049.8% |
| 2009 | -28.74 Thousand USD | -669.28% |
| 2008 | -3737.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -1.66 Million USD | 0.0% |
| 2024 Q2 | 288.47 Thousand USD | 0.0% |
| 2024 FY | - USD | 125.4% |
| 2024 Q3 | -1.66 Million USD | -678.83% |
| 2024 Q1 | 288.47 Thousand USD | 102.94% |
| 2023 Q2 | -307.07 Thousand USD | 0.0% |
| 2023 Q1 | -307.07 Thousand USD | 79.1% |
| 2023 Q3 | -9.8 Million USD | -3093.45% |
| 2023 Q4 | -9.8 Million USD | 0.0% |
| 2023 FY | - USD | -1589.35% |
| 2022 Q2 | 180.52 Thousand USD | 100.0% |
| 2022 Q3 | -762.03 Thousand USD | -522.13% |
| 2022 Q4 | -1.46 Million USD | -92.79% |
| 2022 Q1 | 90.25 Thousand USD | -63.52% |
| 2022 FY | - USD | 92.78% |
| 2021 FY | - USD | -74.0% |
| 2021 Q1 | 561.79 Thousand USD | 167.0% |
| 2021 Q3 | -6.21 Million USD | -545.33% |
| 2021 Q4 | 247.39 Thousand USD | 103.98% |
| 2021 Q2 | -963.53 Thousand USD | -271.51% |
| 2020 FY | - USD | -404.69% |
| 2020 Q4 | -838.49 Thousand USD | -180.29% |
| 2020 Q3 | 1.04 Million USD | 231.29% |
| 2020 Q2 | -795.39 Thousand USD | 65.02% |
| 2020 Q1 | -2.27 Million USD | -152.31% |
| 2019 Q4 | 4.34 Million USD | 361.72% |
| 2019 Q2 | -1.29 Million USD | -389.43% |
| 2019 FY | - USD | 107.84% |
| 2019 Q3 | -1.66 Million USD | -28.26% |
| 2019 Q1 | -264.63 Thousand USD | 97.57% |
| 2018 Q2 | -1.49 Million USD | -28.93% |
| 2018 FY | - USD | -534.7% |
| 2018 Q1 | -1.16 Million USD | 53.42% |
| 2018 Q3 | -1.93 Million USD | -29.48% |
| 2018 Q4 | -10.87 Million USD | -461.83% |
| 2017 Q3 | -458.67 Thousand USD | -286.78% |
| 2017 FY | - USD | -376.5% |
| 2017 Q4 | -2.49 Million USD | -442.95% |
| 2017 Q2 | 245.56 Thousand USD | -44.03% |
| 2017 Q1 | 438.72 Thousand USD | 645.63% |
| 2016 Q4 | 58.83 Thousand USD | 130.21% |
| 2016 Q2 | -138.46 Thousand USD | -116.98% |
| 2016 Q3 | -194.77 Thousand USD | -40.67% |
| 2016 FY | - USD | -85.42% |
| 2016 Q1 | 815.37 Thousand USD | -80.61% |
| 2015 Q4 | 4.2 Million USD | 361.68% |
| 2015 Q2 | 463.11 Thousand USD | 1080.12% |
| 2015 Q1 | 39.24 Thousand USD | 102.59% |
| 2015 FY | - USD | 156.62% |
| 2015 Q3 | 910.92 Thousand USD | 96.69% |
| 2014 Q2 | 49.99 Thousand USD | 134.66% |
| 2014 Q3 | -8.31 Million USD | -16728.05% |
| 2014 Q4 | -1.51 Million USD | 81.75% |
| 2014 Q1 | -144.22 Thousand USD | 98.38% |
| 2014 FY | - USD | -18.65% |
| 2013 Q2 | 2.14 Million USD | 103.74% |
| 2013 Q4 | -8.9 Million USD | -235.43% |
| 2013 Q3 | -2.65 Million USD | -223.94% |
| 2013 Q1 | 1.05 Million USD | -46.4% |
| 2013 FY | - USD | -166.82% |
| 2012 Q4 | 1.96 Million USD | -36.33% |
| 2012 FY | - USD | 1.02% |
| 2012 Q3 | 3.07 Million USD | 7.63% |
| 2012 Q2 | 2.86 Million USD | -37.75% |
| 2012 Q1 | 4.59 Million USD | 30.96% |
| 2011 Q1 | 3.16 Million USD | -35.8% |
| 2011 Q4 | 3.5 Million USD | 22.37% |
| 2011 Q3 | 2.86 Million USD | 2.19% |
| 2011 FY | - USD | -6.21% |
| 2011 Q2 | 2.8 Million USD | -11.32% |
| 2010 FY | - USD | 46049.8% |
| 2010 Q4 | 4.93 Million USD | 40.03% |
| 2010 Q2 | 2.33 Million USD | 198179.69% |
| 2010 Q3 | 3.52 Million USD | 50.88% |
| 2010 Q1 | 1177.00 USD | 127.62% |
| 2009 Q4 | -4261.00 USD | 22.37% |
| 2009 Q1 | -4001.00 USD | 76.2% |
| 2009 Q3 | -5489.00 USD | -380.23% |
| 2009 FY | - USD | -669.28% |
| 2009 Q2 | -1143.00 USD | 71.43% |
| 2008 Q2 | -859.00 USD | 0.0% |
| 2008 Q4 | -16.8 Thousand USD | -137.45% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | -7079.00 USD | -724.1% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -22.13 Million USD | 105.543% |
| BIMI International Medical Inc. | -15.33 Million USD | 107.998% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 9.72 Million USD | 87.382% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 9.72 Million USD | 87.382% |
| Leafly Holdings, Inc. | -5.73 Million USD | 121.396% |
| Leafly Holdings, Inc. | -5.73 Million USD | 121.396% |
| LifeMD, Inc. | -8.21 Million USD | 114.936% |
| LifeMD, Inc. | -8.21 Million USD | 114.936% |
| TRxADE HEALTH, Inc. | -13.72 Million USD | 108.942% |
| PetMed Express, Inc. | -394 Thousand USD | 411.382% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 100.011% |